Researchers are calling for urgent investment in the prevention of a devastating emerging disease that kills tens of thousands of people each year. Researchers report on the frequency of a range of serious complications and very high risk for death among patients with found non-typhoidal Salmonella invasive disease. Non-typhoidal Salmonella invasive disease patients and the disease has a 15 per cent fatality ratio.
Non-typhoidal Salmonella invasive disease is an emerging neglected infectious disease that affects mainly young children and immunocompromised adults in sub-Saharan Africa. It affects more than half a million people a year and is fatal in 15 per cent of cases -- about 77,500 deaths worldwide annually.
The Vacc-iNTS Consortium is working on phase 1 trials of a candidate vaccine, but global support, funding and awareness are needed. The study refines the burden of the disease and justifies vaccine development efforts.
The Vacc-iNTS Consortium is a five-year project and has a NZ$11.8 million budget, funded by the European Union's Horizon 2020 Research and Innovation Programme.
Christian S Marchello, et al Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis. The Lancet Infectious Diseases, 2022; DOI: 10.1016/S1473-3099(21)00615-0
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources